MXPA03005257A - Composiciones frarmaceuticas de un agonista del receptor de nmda. - Google Patents

Composiciones frarmaceuticas de un agonista del receptor de nmda.

Info

Publication number: MXPA03005257A
Authority: MX; Mexico
Prior art keywords: pharmaceutical compositions; receptor agonist; nmda receptor; agonist pharmaceutical; nmda
Prior art date: 2000-12-13

Application number

MXPA03005257A

Other languages

English (en)

Inventor

Jinyang Hong

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-13

Filing date

2001-12-05

Publication date

2003-09-25

2001-12-05 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2003-09-25 Publication of MXPA03005257A publication Critical patent/MXPA03005257A/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Diabetes (AREA)
Inorganic Chemistry (AREA)
Dermatology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Urology & Nephrology (AREA)
Addiction (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

MXPA03005257A 2000-12-13 2001-12-05 Composiciones frarmaceuticas de un agonista del receptor de nmda. MXPA03005257A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25537200P	2000-12-13	2000-12-13
BO0102359		2001-12-05

Publications (1)

Publication Number	Publication Date
MXPA03005257A true MXPA03005257A (es)	2003-09-25

Family

ID=22968017

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MXPA03005257A MXPA03005257A (es)	2000-12-13	2001-12-05	Composiciones frarmaceuticas de un agonista del receptor de nmda.

Country Status (41)

Country	Link
US (2)	US6635270B2 (es)
EP (1)	EP1347760B1 (es)
JP (1)	JP2004515529A (es)
KR (1)	KR100533407B1 (es)
CN (1)	CN1273135C (es)
AP (1)	AP1235A (es)
AR (1)	AR035607A1 (es)
AT (1)	ATE296629T1 (es)
AU (2)	AU1845402A (es)
BG (1)	BG107788A (es)
BR (1)	BR0116085A (es)
CA (1)	CA2431172A1 (es)
CZ (1)	CZ20031543A3 (es)
DE (1)	DE60111265T2 (es)
DO (1)	DOP2001000300A (es)
DZ (1)	DZ3484A1 (es)
EA (1)	EA006489B1 (es)
EC (1)	ECSP034655A (es)
EE (1)	EE200300284A (es)
ES (1)	ES2239648T3 (es)
GE (1)	GEP20053568B (es)
HR (1)	HRP20030473A2 (es)
HU (1)	HUP0400645A2 (es)
IL (1)	IL155810A0 (es)
IS (1)	IS6811A (es)
MA (1)	MA26970A1 (es)
MX (1)	MXPA03005257A (es)
NO (1)	NO20032678D0 (es)
NZ (1)	NZ525742A (es)
OA (1)	OA12414A (es)
PA (1)	PA8534901A1 (es)
PE (1)	PE20020710A1 (es)
PL (1)	PL362080A1 (es)
PT (1)	PT1347760E (es)
SK (1)	SK6982003A3 (es)
TN (1)	TNSN01173A1 (es)
UA (1)	UA73619C2 (es)
UY (1)	UY27068A1 (es)
WO (1)	WO2002047685A2 (es)
YU (1)	YU41103A (es)
ZA (1)	ZA200303892B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2368554T3 (pl)	2003-04-08	2015-05-29	Progenics Pharm Inc	Preparaty farmaceutyczne zawierające metylonaltrekson
TW200800959A (en) *	2005-06-10	2008-01-01	Wyeth Corp	Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
TW200808740A (en) *	2006-06-09	2008-02-16	Wyeth Corp	Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
TW200808741A (en) *	2006-06-09	2008-02-16	Wyeth Corp	6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
TW200811144A (en) *	2006-06-09	2008-03-01	Wyeth Corp	Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
TWI489984B (zh)	2006-08-04	2015-07-01	Wyeth Corp	用於非經腸道傳輸化合物之配方及其用途
AR063984A1 (es) *	2006-11-28	2009-03-04	Wyeth Corp	Metabolitos de 5-fluoro-8-{4-[4-(6-metoxiquinolin-8-il)piperazin-1-il]piperidin-1-il}quinolina, metodos de preparacion, su uso en la fabricacion de medicamentos para el tratamiento de trastornos relacionados con 5-ht1a, composicion farmaceutica que los comprende, compuestos radioetiquetados derivado
CL2008000119A1 (es) *	2007-01-16	2008-05-16	Wyeth Corp	Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
CN101317844B (zh) *	2007-06-08	2010-11-17	章劲夫	化合物(+)-5-甲基-10，11-二氢-5H-二苯并〔a，d〕环庚烯-5，10-亚胺在制备避孕药物中的应用
BRPI0918868B8 (pt)	2008-09-18	2021-05-25	Naurex Inc	compostos moduladores do receptor de nmda e composições compreendendo os mesmos
US8951968B2 (en)	2009-10-05	2015-02-10	Northwestern University	Methods of treating depression and other related diseases
KR101692275B1 (ko)	2010-02-11	2017-01-04	노오쓰웨스턴 유니버시티	２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
BR112012020142A2 (pt)	2010-02-11	2020-08-18	Northwestern University	moduladores do receptor de nmda com estrutura secundária estabilizada e usos dos mesmos.
CN102586243A (zh) *	2012-03-08	2012-07-18	中国人民解放军军事医学科学院放射与辐射医学研究所	一种预防电磁辐射致脑损伤的标志物
EP3610890A1 (en)	2012-11-14	2020-02-19	The Johns Hopkins University	Methods and compositions for treating schizophrenia
EP2951182B1 (en)	2013-01-29	2020-03-18	Aptinyx Inc.	Spiro-lactam nmda receptor modulators and uses thereof
WO2014120800A1 (en)	2013-01-29	2014-08-07	Naurex, Inc.	Spiro-lactam nmda receptor modulators and uses thereof
CA2899010A1 (en)	2013-01-29	2014-08-07	Naurex, Inc.	Spiro-lactam nmda receptor modulators and uses thereof
PL2951183T3 (pl)	2013-01-29	2019-08-30	Aptinyx Inc.	Spiro-laktamowe modulatory receptora NMDA i ich zastosowania
BR112015018092A2 (pt)	2013-01-29	2017-07-18	Naurex Inc	moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
MX2016008369A (es) *	2013-12-23	2016-12-15	Samyang Biopharmaceuticals	Composicion farmaceutica que incluye palonosetron.
EP3458458B1 (en)	2016-05-19	2020-11-04	Aptinyx Inc.	Spiro-lactam nmda receptor modulators and uses thereof
WO2017201285A1 (en)	2016-05-19	2017-11-23	Aptinyx Inc.	Spiro-lactam nmda receptor modulators and uses thereof
AU2017305240B2 (en)	2016-08-01	2021-12-09	Aptinyx Inc.	Spiro-lactam NMDA receptor modulators and uses thereof
WO2018026792A1 (en)	2016-08-01	2018-02-08	Aptinyx Inc.	Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
ES2974090T3 (es)	2016-08-01	2024-06-25	Tenacia Biotechnology Hong Kong Co Ltd	Moduladores de NMDA de espirolactama y métodos de uso de los mismos
PE20190500A1 (es)	2016-08-01	2019-04-10	Aptinyx Inc	Moduladores del receptor nmda spiro-lactam y uso de los mismos
PE20190503A1 (es)	2016-08-01	2019-04-10	Aptinyx Inc	Moduladores del receptor nmda espiro-lactam y uso de los mismos
CA3089561A1 (en)	2018-01-31	2019-08-08	Aptinyx Inc.	Spiro-lactam nmda receptor modulators and uses thereof
US12012413B2 (en)	2019-11-11	2024-06-18	Tenacia Biotechnology (Hong Kong) Co., Limited	Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5272160A (en) *	1989-05-17	1993-12-21	Pfizer Inc	2-piperidino-1-alkanol derivatives as antiischemic agents
US5710168A (en) *	1991-10-23	1998-01-20	Pfizer Inc.	2-piperidino-1-alkanol derivatives as neuroprotective agents
IL122649A (en) *	1995-08-11	2001-08-26	Pfizer	(1s, 2s) - 1- (4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol methanesulfonate trihydrate, its use in the preparation of medicaments and pharmaceutical compositions comprising same
TW450807B (en) *	1995-09-15	2001-08-21	Pfizer	Pharmaceutical compositions for treating tinnitus comprising neuroprotective agents

2001
- 2001-05-12 UA UA2003065485A patent/UA73619C2/uk unknown
- 2001-12-05 YU YU41103A patent/YU41103A/sh unknown
- 2001-12-05 AT AT01270205T patent/ATE296629T1/de not_active IP Right Cessation
- 2001-12-05 DZ DZ013484A patent/DZ3484A1/fr active
- 2001-12-05 EE EEP200300284A patent/EE200300284A/xx unknown
- 2001-12-05 SK SK698-2003A patent/SK6982003A3/sk unknown
- 2001-12-05 OA OA1200300145A patent/OA12414A/en unknown
- 2001-12-05 MX MXPA03005257A patent/MXPA03005257A/es active IP Right Grant
- 2001-12-05 WO PCT/IB2001/002359 patent/WO2002047685A2/en not_active Application Discontinuation
- 2001-12-05 CZ CZ20031543A patent/CZ20031543A3/cs unknown
- 2001-12-05 EA EA200300514A patent/EA006489B1/ru not_active IP Right Cessation
- 2001-12-05 GE GE5171A patent/GEP20053568B/en unknown
- 2001-12-05 US US10/010,827 patent/US6635270B2/en not_active Expired - Fee Related
- 2001-12-05 PL PL01362080A patent/PL362080A1/xx not_active Application Discontinuation
- 2001-12-05 DE DE60111265T patent/DE60111265T2/de not_active Expired - Fee Related
- 2001-12-05 ES ES01270205T patent/ES2239648T3/es not_active Expired - Lifetime
- 2001-12-05 AU AU1845402A patent/AU1845402A/xx active Pending
- 2001-12-05 JP JP2002549256A patent/JP2004515529A/ja active Pending
- 2001-12-05 PT PT01270205T patent/PT1347760E/pt unknown
- 2001-12-05 BR BR0116085-0A patent/BR0116085A/pt not_active IP Right Cessation
- 2001-12-05 CN CNB018203922A patent/CN1273135C/zh not_active Expired - Fee Related
- 2001-12-05 EP EP01270205A patent/EP1347760B1/en not_active Expired - Lifetime
- 2001-12-05 NZ NZ525742A patent/NZ525742A/en unknown
- 2001-12-05 AU AU2002218454A patent/AU2002218454B2/en not_active Ceased
- 2001-12-05 HR HR20030473A patent/HRP20030473A2/hr not_active Application Discontinuation
- 2001-12-05 CA CA002431172A patent/CA2431172A1/en not_active Abandoned
- 2001-12-05 IL IL15581001A patent/IL155810A0/xx unknown
- 2001-12-05 HU HU0400645A patent/HUP0400645A2/hu unknown
- 2001-12-05 KR KR10-2003-7007874A patent/KR100533407B1/ko not_active Expired - Fee Related
- 2001-12-10 DO DO2001000300A patent/DOP2001000300A/es unknown
- 2001-12-11 AR ARP010105748A patent/AR035607A1/es unknown
- 2001-12-11 PE PE2001001235A patent/PE20020710A1/es not_active Application Discontinuation
- 2001-12-12 UY UY27068A patent/UY27068A1/es not_active Application Discontinuation
- 2001-12-12 TN TNTNSN01173A patent/TNSN01173A1/fr unknown
- 2001-12-13 PA PA20018534901A patent/PA8534901A1/es unknown
- 2001-12-13 AP APAP/P/2001/002376A patent/AP1235A/en active
2003
- 2003-05-08 IS IS6811A patent/IS6811A/is unknown
- 2003-05-09 BG BG107788A patent/BG107788A/bg unknown
- 2003-05-20 ZA ZA200303892A patent/ZA200303892B/en unknown
- 2003-06-03 MA MA27191A patent/MA26970A1/fr unknown
- 2003-06-12 NO NO20032678A patent/NO20032678D0/no not_active Application Discontinuation
- 2003-06-13 EC EC2003004655A patent/ECSP034655A/es unknown
- 2003-08-19 US US10/643,441 patent/US20040039022A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NO20032678L (no)	2003-06-12
SK6982003A3 (en)	2004-08-03
EP1347760A2 (en)	2003-10-01
PE20020710A1 (es)	2002-08-09
CA2431172A1 (en)	2002-06-20
AU2002218454B2 (en)	2005-10-27
CN1273135C (zh)	2006-09-06
UY27068A1 (es)	2002-07-31
UA73619C2 (en)	2005-08-15
WO2002047685A3 (en)	2002-08-15
EE200300284A (et)	2003-10-15
DE60111265D1 (de)	2005-07-07
GEP20053568B (en)	2005-07-11
PT1347760E (pt)	2005-09-30
YU41103A (sh)	2006-05-25
IL155810A0 (en)	2003-12-23
AP1235A (en)	2004-01-06
NO20032678D0 (no)	2003-06-12
ES2239648T3 (es)	2005-10-01
TNSN01173A1 (fr)	2005-11-10
WO2002047685A2 (en)	2002-06-20
AP2001002376A0 (en)	2001-12-31
JP2004515529A (ja)	2004-05-27
KR20030070060A (ko)	2003-08-27
PL362080A1 (en)	2004-10-18
CN1479617A (zh)	2004-03-03
ZA200303892B (en)	2004-05-20
US20040039022A1 (en)	2004-02-26
DOP2001000300A (es)	2002-05-30
HRP20030473A2 (en)	2005-04-30
MA26970A1 (fr)	2004-12-20
PA8534901A1 (es)	2002-08-26
EP1347760B1 (en)	2005-06-01
AR035607A1 (es)	2004-06-16
BR0116085A (pt)	2003-12-23
KR100533407B1 (ko)	2005-12-02
NZ525742A (en)	2005-07-29
DZ3484A1 (fr)	2002-06-20
US20020111366A1 (en)	2002-08-15
CZ20031543A3 (cs)	2004-06-16
EA006489B1 (ru)	2005-12-29
ATE296629T1 (de)	2005-06-15
AU1845402A (en)	2002-06-24
DE60111265T2 (de)	2006-05-04
BG107788A (bg)	2004-01-30
IS6811A (is)	2003-05-08
EA200300514A1 (ru)	2003-10-30
OA12414A (en)	2006-04-18
ECSP034655A (es)	2003-07-25
HK1059575A1 (en)	2004-07-09
US6635270B2 (en)	2003-10-21
HUP0400645A2 (hu)	2004-06-28

Publication	Publication Date	Title
MXPA03005257A (es)	2003-09-25	Composiciones frarmaceuticas de un agonista del receptor de nmda.
AU2002210782A1 (en)	2002-05-06	Amide derivatives as nmda receptor antagonists
MXPA02002546A (es)	2003-07-21	Composiciones farmaceuticas que comprenden un receptor agonista o antagonista de la adenosina.
ZA200003998B (en)	2000-08-14	Pharmaceutical compositions.
MXPA03000771A (es)	2003-06-04	Nuevas composiciones farmaceuticas.
MXPA03003235A (es)	2003-10-15	Formulaciones farmaceuticas de liberacion retrasada.
HUP0301777A3 (en)	2010-09-28	Aniline-derived ligands for the thyroid receptor, pharmaceutical compositions comprising thereof and their use
HUP0300541A3 (en)	2009-04-28	Pharmaceutical compositions for sustained release, containing fluvastatin
EG24194A (en)	2008-10-14	5ht-a-partial agonist pharmaceutical compositions
GB0009584D0 (en)	2000-06-07	Pharmaceutical compositions
AU2001296013A1 (en)	2002-05-15	Pgd2 receptor antagonistic pharmaceutical compositions
ZA200210359B (en)	2003-11-13	Pharmaceutical compositions.
IL161997A0 (en)	2005-11-20	Pharmaceutical composition comprising a 5ht1 receptor agonist
HUP0300419A3 (en)	2005-07-28	Estrogen agonist/antagonist metabolites, pharmaceutical compositions containing them and their use
MXPA03002105A (es)	2003-06-19	Composiciones farmaceuticas.
EP1296958A4 (en)	2004-01-28	ANTIAGONISTS OF NMDA NR2B RECEPTORS OF IMINOPYRIMIDINE
AU2001286409A1 (en)	2002-02-18	N-methyl-d-aspartate receptor antagonists
GB0008485D0 (en)	2000-05-24	Pharmaceutical compositions
GB0009613D0 (en)	2000-06-07	Pharmaceutical compositions
AU2002335093A1 (en)	2003-04-28	Nr3b nmda receptor subunit compositions and related methods
IL152205A0 (en)	2003-05-29	A solid dispersion, pharmaceutical compositions containing the same and methods for the preparation thereof
SI1347760T1 (en)	2005-10-31	Nmda receptor agonist pharmaceutical compositions
IL154414A0 (en)	2003-09-17	Pharmaceutical compositions containing an indolinyl-2,2-dimethylpropanamide
GB0015901D0 (en)	2000-08-23	Compositions containing 5ht receptor agonists
ZA200005850B (en)	2002-05-17	β2- Adrenergic receptor agonists.

Legal Events

Date	Code	Title	Description
2006-01-10	FG	Grant or registration